Assetmark Inc. Acquires 21,553 Shares of Novo Nordisk A/S (NYSE:NVO)

Assetmark Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 441,882 shares of the company’s stock after acquiring an additional 21,553 shares during the quarter. Assetmark Inc.’s holdings in Novo Nordisk A/S were worth $52,615,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Verdence Capital Advisors LLC grew its position in Novo Nordisk A/S by 18.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 42,977 shares of the company’s stock worth $5,117,000 after purchasing an additional 6,821 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $42,000. Stiles Financial Services Inc increased its position in shares of Novo Nordisk A/S by 1.0% during the third quarter. Stiles Financial Services Inc now owns 44,962 shares of the company’s stock valued at $5,354,000 after acquiring an additional 436 shares during the last quarter. Winthrop Advisory Group LLC bought a new stake in Novo Nordisk A/S during the third quarter worth $234,000. Finally, Lewis Asset Management LLC boosted its position in Novo Nordisk A/S by 3.4% in the third quarter. Lewis Asset Management LLC now owns 5,472 shares of the company’s stock worth $652,000 after purchasing an additional 182 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.4 %

Shares of NYSE NVO opened at $107.20 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The company has a market cap of $481.06 billion, a P/E ratio of 34.69, a P/E/G ratio of 1.44 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The business has a 50-day simple moving average of $121.42 and a two-hundred day simple moving average of $130.30.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The firm had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 89.69%. Research analysts anticipate that Novo Nordisk A/S will post 2.87 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.